Zura Bio (NASDAQ:ZURA) Given New $12.00 Price Target at Chardan Capital

Zura Bio (NASDAQ:ZURA - Get Free Report) had its target price reduced by research analysts at Chardan Capital from $14.00 to $12.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Chardan Capital's price target suggests a potential upside of 155.32% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Friday, October 18th. HC Wainwright reaffirmed a "neutral" rating and issued a $5.00 target price on shares of Zura Bio in a report on Monday, October 21st. Piper Sandler restated an "overweight" rating and issued a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Leerink Partnrs raised Zura Bio to a "strong-buy" rating in a research report on Monday, November 4th. Finally, Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They issued an "outperform" rating and a $15.00 price target on the stock. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $15.80.

Zura Bio Trading Up 2.6 %

Shares of NASDAQ:ZURA traded up $0.12 during trading on Friday, hitting $4.70. 193,768 shares of the company's stock traded hands, compared to its average volume of 325,986. The company has a 50-day moving average price of $4.18 and a 200-day moving average price of $4.12. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sell-side analysts expect that Zura Bio will post -0.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 22.10% of the company's stock.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. purchased a new stake in Zura Bio in the second quarter worth approximately $8,446,000. Great Point Partners LLC boosted its stake in shares of Zura Bio by 68.3% during the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the period. Armistice Capital LLC boosted its stake in shares of Zura Bio by 53.2% during the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares during the period. Affinity Asset Advisors LLC purchased a new stake in shares of Zura Bio during the first quarter valued at approximately $1,157,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Zura Bio during the third quarter valued at approximately $156,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.